Foghorn Therapeutics Inc.
General ticker "FHTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $306.4M (TTM average)
Foghorn Therapeutics Inc. follows the US Stock Market performance with the rate: 33.3%.
Estimated limits based on current volatility of 3.8%: low 4.29$, high 4.63$
Factors to consider:
- Total employees count: 112 (-3.4%) as of 2024
- Top business risk factors: Operational and conduct risks, Key executive dependency, Limited operating history, Geopolitical risks, Product development risks
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [3.68$, 9.22$]
- 2025-12-31 to 2026-12-31 estimated range: [3.14$, 8.11$]
Financial Metrics affecting the FHTX estimates:
- Positive: with PPE of -3.0 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -37.22 <= 0.33
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Shareholder equity ratio, % of -16.03 <= 18.93
Short-term FHTX quotes
Long-term FHTX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $19.23MM | $34.16MM | $22.60MM |
| Operating Expenses | $136.37MM | $142.06MM | $125.28MM |
| Operating Income | $-117.14MM | $-107.91MM | $-102.68MM |
| Non-Operating Income | $8.26MM | $13.71MM | $16.06MM |
| R&D Expense | $105.62MM | $109.69MM | $94.53MM |
| Income(Loss) | $-108.88MM | $-94.20MM | $-86.62MM |
| Taxes | $0.00MM | $4.23MM | $0.00MM |
| Profit(Loss)* | $-108.88MM | $-98.43MM | $-86.62MM |
| Stockholders Equity | $0.11MM | $-77.19MM | $-45.53MM |
| Assets | $404.88MM | $285.92MM | $283.98MM |
| Operating Cash Flow | $193.61MM | $-118.11MM | $-100.41MM |
| Capital expenditure | $1.21MM | $1.22MM | $0.91MM |
| Investing Cash Flow | $-244.32MM | $144.45MM | $-29.90MM |
| Financing Cash Flow | $1.76MM | $1.78MM | $105.43MM |
| Earnings Per Share** | $-2.62 | $-2.34 | $-1.58 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.